• 1
    Haber JE. DNA recombination: the replication connection. Trends Biochem Sci 1999; 24: 2715.
  • 2
    Morgan WF, Corcoran J, Hartmann A, Kaplan MI, Limoli CL, Ponnaiya B. DNA double-strand breaks, chromosomal rearrangements, and genomic instability. Mutat Res 1998; 40: 1258.
  • 3
    Thacker J. The role of homologous recombination processes in the repair of severe forms of DNA damage in mammalian cells. Biochimie 1999; 81: 7785.
  • 4
    Critchlow SE, Jackson SP. DNA end joining: from yeast to man. Trends Biochem Sci 1998; 23: 3948.
  • 5
    Khanna KK, Jackson SP. DNA double-strand breaks: signalling, repair and the cancer connection. Nat Genet 2001; 27: 24754.
  • 6
    Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 13445.
  • 7
    The Breast Cancer Linkage Consortium. Cancer risk in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 13106.
  • 8
    Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000; 26: 3624.
  • 9
    Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, Green A, Healey CS, Redman K, Dunning AM, Pharoah PD, Easton DF, et al. BRCA2 Asp372His polymorphism and epithelial ovarian cancer risk. Int J Cancer 2002; 103: 42730.
  • 10
    Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BAJ, Pharoah PDP, Dunning A. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 2002; 11: 19.
  • 11
    Han J, Colditz GA, Samsom LD, Hunter DJ. Polymorphisms in DNA double-strand break repair genes and skin cancer risk. Cancer Res 2004; 64: 300913.
  • 12
    Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologues recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004; 10: 267580.
  • 13
    Deans B, Griffin CS, O'Regan P, Jasin M, Thacker J. Homologous recombination deficiency leads to profound genetic instability in cells derived from XRCC2-knockout mice. Cancer Res 2003; 63: 81817.
  • 14
    Brenneman MA, Wagener BM, Miller CA, Allen C, Nickoloff JA. XRCC3 controls the fidelity of homologous recombination: roles for XRCC3 in late stages of recombination. Mol Cell 2002; 10: 38795.
  • 15
    DiSaia PJ, Creasman WT. Clinical gynecologic oncology. 6th ed. St. Louis : Mosby Inc., 2002. p 289.
  • 16
    Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia? Lancet 1971; 2: 163.
  • 17
    Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992; 84: 592601.
  • 18
    Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F, Beral V, Boyle P, Trichopoulus D. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991; 49: 506.
  • 19
    Francheschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, Tzonou A, Trichopoulos D. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int J Cancer 1991; 49: 615.
  • 20
    Adami H-O, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson PO. Parity, age at first childbirth and risk of ovarian cancer. Lancet 1994; 344: 12504.
  • 21
    Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995; 76: 28490.
  • 22
    Pharoah PD, Ponder BA. The genetics of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002; 16: 44968.
  • 23
    Lum A, LeMarchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomark Prev 1998; 8: 71924.
  • 24
    Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BA. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336: 112530.
  • 25
    Stratton JF, Thompson D, Bobrow L, Dalal N, Gore M, Bishop DT, Scott T, Evans G, Daly P, Easton DF, Ponder BA. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet 1999; 65: 172532.
  • 26
    Cordell HJ, Clayton DG. A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. Am J Hum Genet 2002; 70: 12441.
  • 27
    Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598604.
  • 28
    Rafii S, O'Regan P, Xinarianos G, Azmy I, Stephenson T, Reed M, Meuth M, Thacker J, Cox A. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet 2002; 11: 14338.
  • 29
    Han J, Hankinson SE, Zhang SM, De Vivo I, Hunter DJ. Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk. Cancer Epidemiol Biomark Prev 2004; 13: 5204.
  • 30
    Cozen W, Peters R, Reichardt JK, Ng W, Felix JC, Wan P, Pike MC. Galactose 1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes Control 2002; 13: 11320.
  • 31
    Santarosa M, Bidoli E, Gallo A, Steffan A, Bolocchi M, Viel A. Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer. Oncol Rep 2002; 9: 63944.
  • 32
    Garner EL, Stokes EE, Berkowitz RS, Mok SC, Cramer DW. Polymorphisms of the estrogen metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002; 62: 305862.
  • 33
    Aktas D, Guney I, Alikasifoglu M, Yuce K, Tuncbilek E, Ayhan A. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 2002; 86: 1248.
  • 34
    Terry KL, Titus-Ernstoff L, Garner EO, Vitonis AF, Cramer DW. Interaction between CYP1A1 polymorphic variants and dietary exposures influencing ovarian cancer risk. Cancer Epidemiol Biomark Prev 2003; 12: 18790.
  • 35
    Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, Beckmann MW, Zeillinger R, Koelbl H, Tempfer CB. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 2003; 63: 30668.
  • 36
    Fung WL, Risch H, McLaughlin J, Rosen B, Cole D, Vesprini D, Nar SA. The N341D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer. Cancer Epidemiol Biomark Prev 2003; 12: 67880.
  • 37
    Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley RC, Lancaster JM, Schildkraut J, Marks J, Berchuk A. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig 2003; 10: 3817.
  • 38
    Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RO, Marks J, Berchuk A. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res 2003; 12: 4396403.
  • 39
    Schouli J, Mustea A, Koensgen D, Chen FC, Lichtenegger W. Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer. Ann Oncol 2003; 14: 15014.